))
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
Manage episode 415602474 series 3382903
เนื้อหาจัดทำโดย ReachMD เนื้อหาพอดแคสต์ทั้งหมด รวมถึงตอน กราฟิก และคำอธิบายพอดแคสต์ได้รับการอัปโหลดและจัดหาให้โดยตรงจาก ReachMD หรือพันธมิตรแพลตฟอร์มพอดแคสต์ของพวกเขา หากคุณเชื่อว่ามีบุคคลอื่นใช้งานที่มีลิขสิทธิ์ของคุณโดยไม่ได้รับอนุญาต คุณสามารถปฏิบัติตามขั้นตอนที่แสดงไว้ที่นี่ https://th.player.fm/legal
Host: Sara M. Tolaney, MD, MPH
The emergence of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer, with emerging evidence supporting their utility in the early breast cancer (eBC) setting in combination with adjuvant endocrine therapy.
…
continue reading
The emergence of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) metastatic breast cancer, with emerging evidence supporting their utility in the early breast cancer (eBC) setting in combination with adjuvant endocrine therapy.
In this educational activity, expert faculty review a clinical case series highlighting the application of CDK4/6 inhibitors in HR+/HER2− eBC, including identification of patients at high risk of recurrence/progression, selection of adjuvant therapy based on the latest clinical evidence and patient-specific factors, and management of treatment-related adverse events. Approaches to recognizing and addressing racial/ethnic health disparities among minority patients will also be discussed, empowering clinicians to make informed decisions that align with achieving health equity.
718 ตอน
แบ่งปัน
